RT Journal Article
SR Electronic
T1 Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.01.21268271
DO 10.1101/2022.01.01.21268271
A1 María Eugenia Toledo-Romani
A1 Mayra García-Carmenate
A1 Leslyhana Verdecia-Sánchez
A1 Suzel Pérez-Rodríguez
A1 Meybis Rodriguez-González
A1 Carmen Valenzuela-Silva
A1 Beatriz Paredes-Moreno
A1 Belinda Sanchez-Ramirez
A1 Raúl González-Mugica
A1 Tays Hernández-Garcia
A1 Ivette Orosa-Vázquez
A1 Marianniz Díaz-Hernández
A1 María Teresa Pérez-Guevara
A1 Juliet Enriquez-Puertas
A1 Enrique Noa-Romero
A1 Ariel Palenzuela-Diaz
A1 Gerardo Baro-Roman
A1 Ivis Mendoza-Hernández
A1 Yaima Muñoz
A1 Yanet Gómez-Maceo
A1 Bertha Leysi Santos-Vega
A1 Sonsire Fernandez-Castillo
A1 Yanet Climent-Ruiz
A1 Laura Rodríguez-Noda
A1 Darielys Santana-Mederos
A1 Yanelda García-Vega
A1 Guang Wu-Chen
A1 Delaram Doroud
A1 Alireza Biglari
A1 Tammy Boggiano-Ayo
A1 Yury Valdés-Balbín
A1 Daniel García-Rivera
A1 Dagmar García-Rivera
A1 Vicente Vérez-Bencomo
A1 SOBERANA Research Group
YR 2022
UL http://medrxiv.org/content/early/2022/01/05/2022.01.01.21268271.abstract
AB Background We report results of immunogenicity, safety and reactogenicity of SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults in a phase IIb clinical trial.Method This phase IIb trial was designed as parallel, multicentre, adaptive, double blind, randomized and placebo-controlled. Subjects (N=810) aged 19-80 years were randomized to receive two doses of the recombinant SARS CoV-2 receptor binding domain (RBD) conjugated to tetanus toxoid (SOBERANA 02) and a third dose of dimeric RBD (SOBERANA Plus) 28 days apart; two production batches of active ingredient of SOBERANA 02 were evaluated. Primary outcome was the percentage of seroconverted subjects with ≥4-fold the anti-RBD IgG concentration. Secondary outcomes were safety, reactogenicity and neutralizing antibodies.Results Seroconversion rate in vaccinees was respectively 76.3 and 96.8% after two or three doses, compared with 7.3% in placebo group. Anti-RBD IgG increased significantly after first and second dose of SOBERANA 02 respect to placebo group; and the third dose with SOBERANA Plus boosts the response compared to the second dose. Neutralizing IgG antibodies were detected against D614G and VOCs α, β and δ. Specific and functional antibodies were detected at least until 7-8 months after the third dose. The frequency of serious adverse events (AEs) associated with vaccination was very low (0.1%); with only one serious AE consistent with vaccination. Local pain was the most frequent AE.Conclusions Two doses of SOBERANA 02 were well tolerated, safe an immunogenic in adults aged 19-80 years old. The heterologous combination with a third dose of SOBERANA Plus increased neutralizing antibodies, detectable 7-8 months after finishing the vaccination schedule.Trial registry https://rpcec.sld.cu/trials/RPCEC00000347Competing Interest StatementAuthors M.E.T.R., M.G.C., L.V.S., S.P.R, C.V.S, M.T.P.G., J.E.P, E.N.R., A.P.D., G.B.R., I.M.H., Y.M, Y.G.M., B.L.S.V., G.W.C., D.D., A.B., and D.G.R., declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Authors M.R.G., B.P.M., B.S.R., R.G.M., T.H.G., I.O.V., M.D.H., S.F.C., Y.C.R, L.R.N., D.S.M., Y.G.V., T.B.A., Y.V.B., D.G.R., and V.V.B., work at Finlay Vaccine Institute or the Centre of Molecular Immunology, institutions that develop and manufacture the vaccine candidates but they have not received an honorarium for this paper. B.S.R., S.F.C., Y.C.R, L.R.N., D.S.M., Y.V.B., D.G.R., D.G.R. and V.V.B., have filed patent applications related to the vaccine SOBERANA 02.Clinical Trialinternational clinical trial register. https://rpcec.sld.cu/trials/RPCEC00000347Funding StatementThis work was supported by the Finlay Vaccine Institute, BioCubaFarma and the Fondo Nacional de Ciencia y Tecnica (FONCI-CITMA-Cuba, contract 2020-20)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ad hoc centralized Research Ethics Committee from the Medical Sciences University, Faculty of Medicine Manuel Fajardo, Havana, designed by the Health Innovation Committee from the Cuban Ministry of Health (MINSAP)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors